Haiyi Jiang
About
Haiyi Jiang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Haiyi Jiang has authored 53 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Haiyi Jiang's work include Lung Cancer Research Studies (28 papers), Lung Cancer Treatments and Mutations (27 papers) and Cancer therapeutics and mechanisms (13 papers). Haiyi Jiang is often cited by papers focused on Lung Cancer Research Studies (28 papers), Lung Cancer Treatments and Mutations (27 papers) and Cancer therapeutics and mechanisms (13 papers). Haiyi Jiang collaborates with scholars based in Japan, United States and United Kingdom. Haiyi Jiang's co-authors include Masahiro Fukuoka, Nagahiro Saijo, Tony Mok, James Chih‐Hsin Yang, Alison Armour, Yi‐Long Wu, Emma Duffield, Patrapim Sunpaweravong, Sumitra Thongprasert and Yukito Ichinose and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and American Journal of Respiratory and Critical Care Medicine.
In The Last Decade
Haiyi Jiang
51 papers receiving 9.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Haiyi Jiang Japan | 24 | 8.2k | 6.8k | 2.4k | 2.1k | 504 | 53 | 9.9k | ||
| Helena A. Yu United States | 41 | 6.6k 0.8× | 5.5k 0.8× | 3.1k 1.3× | 2.0k 1.0× | 406 0.8× | 195 | 8.4k | ||
| Caicun Zhou China | 39 | 6.8k 0.8× | 6.4k 0.9× | 2.6k 1.1× | 1.6k 0.8× | 448 0.9× | 136 | 8.9k | ||
| Claire Watkins United Kingdom | 21 | 7.8k 1.0× | 7.5k 1.1× | 2.9k 1.2× | 2.1k 1.0× | 660 1.3× | 42 | 11.0k | ||
| David M. Jackman United States | 38 | 5.6k 0.7× | 4.9k 0.7× | 2.0k 0.9× | 1.7k 0.8× | 388 0.8× | 87 | 7.6k | ||
| Daniel B. Costa United States | 49 | 8.4k 1.0× | 6.8k 1.0× | 3.6k 1.5× | 2.2k 1.1× | 476 0.9× | 169 | 10.4k | ||
| Rafał Dziadziuszko Poland | 44 | 6.3k 0.8× | 5.8k 0.8× | 2.7k 1.1× | 1.8k 0.9× | 529 1.0× | 290 | 9.0k | ||
| Takashi Seto Japan | 47 | 6.6k 0.8× | 6.1k 0.9× | 2.2k 0.9× | 1.2k 0.6× | 557 1.1× | 365 | 8.7k | ||
| Patrapim Sunpaweravong Thailand | 16 | 7.1k 0.9× | 5.7k 0.8× | 2.2k 0.9× | 1.9k 0.9× | 579 1.1× | 57 | 8.5k | ||
| Denis Moro‐Sibilot France | 44 | 7.2k 0.9× | 7.2k 1.1× | 2.4k 1.0× | 1.8k 0.9× | 599 1.2× | 282 | 10.5k | ||
| Takayuki Kosaka Japan | 32 | 6.5k 0.8× | 5.6k 0.8× | 3.8k 1.6× | 1.8k 0.9× | 547 1.1× | 93 | 9.3k |
Countries citing papers authored by Haiyi Jiang
Since
Specialization
Citations
This map shows the geographic impact of Haiyi Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haiyi Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haiyi Jiang more than expected).
Fields of papers citing papers by Haiyi Jiang
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Haiyi Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haiyi Jiang. The network helps show where Haiyi Jiang may publish in the future.
Co-authorship network of co-authors of Haiyi Jiang
This figure shows the co-authorship network connecting the top 25 collaborators of Haiyi Jiang. A scholar is included among the top collaborators of Haiyi Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haiyi Jiang. Haiyi Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Cheng, Ying, David R. Spigel, Jian Fang, et al.. (2024). MA17.04 Patient-Reported Outcomes (PROs) With Consolidation Durvalumab Versus Placebo Following cCRT in Limited-Stage SCLC: ADRIATIC. Journal of Thoracic Oncology. 19(10). S124–S125.
2.
Kim, Dong‐Wan, Byoung Chul Cho, Sang‐We Kim, et al.. (2024). Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study. Lung Cancer. 190. 107530–107530.
3.
Reinmuth, Niels, Óscar Juan, Dariusz M. Kowalski, et al.. (2024). Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study. Clinical Cancer Research. 30(18). 4055–4067.
4.
Xie, Mingchao, Jaime Rodriguez‐Canales, Johannes Zimmermann, et al.. (2024). Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Molecular Cancer. 23(1). 115–115.
5.
Chen, Yuanbin, Luis Paz‐Ares, Niels Reinmuth, et al.. (2022). Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report. JTO Clinical and Research Reports. 3(6). 100330–100330.
6.
Robinson, Clifford G., Lijie Xing, Shahed N. Badiyan, et al.. (2022). 122TiP Phase III study of durvalumab with SBRT for unresected stage I/II, lymph-node negative NSCLC (PACIFIC-4/RTOG 3515). Annals of Oncology. 33. S88–S88.
7.
Hotta, Katsuyuki, Makoto Nishio, Haruhiro Saito, et al.. (2021). First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis. International Journal of Clinical Oncology. 26(6). 1073–1082.
8.
Senan, Suresh, Isamu Okamoto, Gyeong‐Won Lee, et al.. (2019). Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study. Clinical Lung Cancer. 21(2). e84–e88.
9.
Itoh, Y., Helen Tomkinson, Martin Johnson, et al.. (2019). Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 83(5). 849–858.
10.
Murakami, Shuji, Mustafa Özgüroğlu, Augusto Villegas, et al.. (2017). PACIFIC: A double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC. Annals of Oncology. 28. x122–x122.
11.
Yang, James Chih‐Hsin, Dong‐Wan Kim, Sang‐We Kim, et al.. (2016). Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study.. Journal of Clinical Oncology. 34(15_suppl). 9002–9002.
12.
Udager, Aaron M., Stephanie L. Skala, Martin J. Magers, et al.. (2016). Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. Annals of Oncology. 27(9). 1706–1712.
13.
Satouchi, Miyako, Yukito Ichinose, Yutaka Nishiwaki, et al.. (2012). Final Analysis of Overall Survival (OS) in the IPASS, an International Multicenter Phase III Study on Gefitinib and Carboplatin/Paclitaxel for Treatment-na^|^iuml;ve NSCLC Patients. Haigan. 52(2). 153–160.
14.
Wu, Yi‐Long, Baohui Han, Xuyi Liu, et al.. (2012). Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China. Asia-Pacific Journal of Clinical Oncology. 8(3). 232–243.
15.
Yamamoto, Nobuyuki, Yutaka Nishiwaki, Shunichi Negoro, et al.. (2010). Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology. 5(7). 1042–1047.
16.
Kudoh, Shoji, Harubumi Kato, Yutaka Nishiwaki, et al.. (2008). Interstitial Lung Disease in Japanese Patients with Lung Cancer. American Journal of Respiratory and Critical Care Medicine. 177(12). 1348–1357.
17.
Kiura, Katsuyuki, Kazuhiko Nakagawa, Tetsu Shinkai, et al.. (2008). A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 3(4). 386–393.
18.
Sekine, Ikuo, Yukito Ichinose, Yutaka Nishiwaki, et al.. (2007). B3-01: A randomized Phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with previously treated advanced non-small-cell lung cancer. Journal of Thoracic Oncology. 2(8). S339–S340.
19.
Tsuboi, Masahiro, Harubumi Kato, Kanji Nagai, et al.. (2005). Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer. Anti-Cancer Drugs. 16(10). 1123–1128.
20.
Müller, Néstor L., Dorothy A. White, Haiyi Jiang, & Akihiko Gemma. (2004). Diagnosis and management of drug-associated interstitial lung disease. British Journal of Cancer. 91(S2). S24–S30.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Helena A. Yu Breakdown of academic impact, for papers by Caicun Zhou Breakdown of academic impact, for papers by Claire Watkins Breakdown of academic impact, for papers by David M. Jackman Breakdown of academic impact, for papers by Daniel B. Costa Breakdown of academic impact, for papers by Rafał Dziadziuszko Breakdown of academic impact, for papers by Takashi Seto Breakdown of academic impact, for papers by Patrapim Sunpaweravong Breakdown of academic impact, for papers by Denis Moro‐Sibilot Breakdown of academic impact, for papers by Takayuki Kosaka